New meta-analysis provides a comprehensive view of real-world data and furthers understanding ofEntyvio as an important treatment option for patients with ulcerative colitis or Crohn's disease ...

Patients with moderate-to-severe ulcerative colitis treated with Entyvio as first-line biologic therapy could experience better outcomes, according to research published in Inflammatory Bowel ...

Three new studies demonstrate long-term clinical benefits of Entyvio in patients with inflammatory bowel disease, regardless of their previous exposure to anti-TNF therapy.Entyvio (vedolizumab ...

Takeda Pharmaceutical Company Limited ("Takeda") today announced new real-world data evaluating the comparative effectiveness of Entyvio(R) (vedolizumab) and tumor necrosis factor-alpha (TNFalpha ...

Patients with ulcerative colitis will get treatment with Takeda’s biologic Entyvio on the National Health Service in England and Wales, after cost regulators issued final guidance on its use. Patients ...

New clinical study also provides data for Entyvio ® in inducing complete mucosal healing and endoscopic remission, particularly in bio-naïve patients OSAKA, Japan, Feb. 16, 2018 /CNW/ - Takeda ...

Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease Patients in Comparative Effectiveness Real-World Data Analysis ...